1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1002/hed.23647" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/hed.23647</a>
Pages
644–649
Issue
5
Volume
37
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Publisher
An entity responsible for making the resource available
Head & neck
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-05
Subject
The topic of the resource
80 and over; Adenocarcinoma/drug therapy/mortality/pathology; adenoid cystic carcinoma; Adenoid Cystic/*drug therapy/mortality/pathology; Adult; Aged; Antineoplastic Agents/*therapeutic use; Carcinoma; Disease-Free Survival; Dose-Response Relationship; Drug; Drug Administration Schedule; Female; gefitinib; Gefitinib; Humans; Local/*drug therapy/mortality/pathology; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness/pathology; Neoplasm Recurrence; Neoplasm Staging; non-adenoid cystic carcinoma; Prognosis; Quinazolines/*therapeutic use; Remission Induction; response to therapy; salivary gland cancer; Salivary Gland Neoplasms/*drug therapy/mortality/pathology; Survival Analysis; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Jakob John A; Kies Merrill S; Glisson Bonnie S; Kupferman Michael E; Liu Diane D; Lee J Jack; El-Naggar Adel K; Gonzalez-Angulo Ana M; Blumenschein George R Jr
Description
An account of the resource
BACKGROUND: The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: We conducted a phase II study in adenoid cystic carcinoma (ACC) and non-ACC. Gefitinib was administered 250 mg orally daily. The primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and disease control rates. EGFR and human epidermal growth factor receptor 2 (HER2) expression were evaluated and correlated with outcomes. RESULTS: Thirty-seven patients were enrolled in this study, and 36 were evaluable (18 with ACC and 18 with non-ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non-ACC, respectively. The disease control rate at 8 weeks was higher in patients with ACC. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. CONCLUSION: We did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/hed.23647" target="_blank" rel="noreferrer noopener">10.1002/hed.23647</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
80 and over
Adenocarcinoma/drug therapy/mortality/pathology
adenoid cystic carcinoma
Adenoid Cystic/*drug therapy/mortality/pathology
Adult
Aged
Antineoplastic Agents/*therapeutic use
Blumenschein George R Jr
Carcinoma
Department of Internal Medicine
Disease-Free Survival
Dose-Response Relationship
Drug
Drug Administration Schedule
El-Naggar Adel K
Female
Gefitinib
Glisson Bonnie S
Gonzalez-Angulo Ana M
Head & neck
Humans
Jakob John A
Kies Merrill S
Kupferman Michael E
Lee J Jack
Liu Diane D
Local/*drug therapy/mortality/pathology
Male
Maximum Tolerated Dose
Middle Aged
NEOMED College of Medicine
Neoplasm Invasiveness/pathology
Neoplasm Recurrence
Neoplasm Staging
non-adenoid cystic carcinoma
Prognosis
Quinazolines/*therapeutic use
Remission Induction
response to therapy
salivary gland cancer
Salivary Gland Neoplasms/*drug therapy/mortality/pathology
Survival Analysis
Treatment Outcome